Therefore, application of IL-36Ra, IL-38 and IL-36R mAbs might be a promising therapeutic way in COVID-19 patients via inhibiting IL-36-mediated hyperinflammation (Figure 2). The gene discussed is IL1F10; the disease is COVID-19.